

09-26-05

27246



Express Mail Label No.: EV695505780US

Date of Deposit: September 22, 2005

Atty. Docket No. 15966-577A CIP3 (CURA 77A CIP3)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Shimkets *et al.*
SERIAL NUMBER: 09/775,482 EXAMINER: Andres, Janet L.
FILING DATE: February 2, 2001 ART UNIT: 1646
FOR: GROWTH FACTOR POLYPEPTIDES AND NUCLEIC ACIDS ENCODING
SAME

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the above-referenced patent application are the following documents which were previously filed on August 15, 2005. A copy of these documents are now being transmitted separately to each case listed on Schedule A, so the documents can be more easily matched up with the relevant file.

1. Revocation by Assignee and New Power of Attorney (2 pgs.)
with attached Schedule A (4 pgs.);
2. Return postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at 617-542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any additional fees that may be due to the undersigned's account, Deposit Account No. 50-0311, Ref. No. 15966-577A CIP3 (CURA 77A CIP3). A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529
Naomi S. Biswas, No. 38,384
Attorneys for Applicant
c/o MINTZ LEVIN
Tel: (617) 542-6000
Fax: (617) 542-2241
Customer No. 30623

Dated: September 22, 2005

Express Mail Label No.: EQ 128341435 US
Date of Deposit: August 15, 2005

Attorney Docket No.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



ASSIGNEE: CuraGen Corporation
SERIAL NUMBER: See Attached Schedule A
FILING DATE: See Attached Schedule A
FOR: See Attached Schedule A

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REVOCATION BY ASSIGNEE AND NEW POWER OF ATTORNEY

CuraGen Corporation, a company and owner ("Assignee") of the patents and patent applications listed on the attached Schedule A, hereby revokes any and all former powers of attorney and hereby appoints the attorneys and/or agents associated with Customer Number 55111, as Applicants' attorneys with full power of substitution and revocation to take any and all action necessary with regard to the patent application.

Please address all telephone calls to Ivor R. Elrifi at telephone number 617/348-1747.


Please address all correspondence to Customer No. 55111.

Best Available Copy

EQ128341435US

The undersigned is authorized to act on behalf of the Assignee in the above-referenced patent application.

Respectfully submitted,



George M. Yahwak, Esq.

TITLE: Director of Intellectual Property

REGISTRATION NO. 26, 824

COMPANY: CuraGen Corporation

Date: Monday, August 15, 2005

TRA 2055379v1

Best Available Copy

Schedule A

U.S. APPLICATIONS

| Docket No. | Title | Filing Date | Application No | Assignment Reel and Frame Nos. |
|-------------------------------|--|------------------|----------------|--------------------------------|
| 21402-018 CURA 318 | Method of Detecting Inflammatory Lung Disorders | May 25, 2001 | 09/865,812 | R# F# Abandoned |
| 21402-018 DIV CURA 318 DIV | Method of Detecting Inflammatory Lung Disorders | July 2, 2003 | 10/613,105 | R# F# |
| 21402-042 CURA 342 | Methods of Detecting and Treating Tuberos Sclerosis Complex Associated Disorders | Dec. 10, 2001 | 10/016,253 | R#013294 F#0484 |
| 21402-048 CURA 348 | Therapeutic Polypeptides, Nucleic Acids Encoding Same, and methods of Use | March 19, 2003 | 10/391,939 | R3 F# |
| 21402-502A CURA 802A | Therapeutic Polypeptides, Nucleic Acids Encoding Same, and Methods of Use | Dec. 2, 2002 | 10/309,290 | R#013968 F#0584 |
| 21402-660 CURA 960 | Compositions and Methods for Treating T-Cell Mediated Pathological Conditions | January 31, 2005 | 11/047,207 | R# F# |
| 15966-557OM CURA 57OM | Compositions and Methods of Use for a Fibroblast Growth Factor | May 9, 2003 | 10/435,087 | R#015013 F#0343 |

Best Available Copy

| Docket No. | Title | Filing Date | Application No. | Assignment Ref and Frame Nos. |
|--|---|-------------------|-----------------|-------------------------------|
| 15966-557 IBD CIP3 CURA57IBDCIP3 | Methods of Preventing an Treating Inflammatory Bowel Disease | Nov. 3, 2004 | 10/890,764 | R# F# |
| 15966-557A IBDCIP2 CURA 57 A IBD CIP2 | Treatment of Inflammatory Bowel Disease Using Growth Factors | Dec. 16, 2002 | 10/321,962 | R# F# |
| 15966-557A IBDCIP CURA 57 A IBDCIP | Treatment of Inflammatory Bowel Disease Using Growth Factors | November 16, 2001 | 10/011,364 | R# F# |
| 15966-557 CON CURA 57 CON | Novel Fibroblast Growth Factor and Nucleic Acids Encoding Same | December 30, 2004 | 11/027,948 | R# F# |
| 15966-557 CIP4 CURA 57CIP4 | Novel Fibroblast Grown Factor and Nucleic Acids Encoding Same | Nov. 3, 2004 | 10/980,659 | R# F# |
| 15966-557 CIP3 CURA 57 CIP3 | Novel Fibroblast Growth Factor and Nucleic Acids Encoding Same | June 17, 2002 | 10/174,394 | R#013630 F#0882 |
| 15966-557 CIP2CON1 CURA 57 CIP2CON1 | Antibodies to Fibroblast Growth Factor and Their Methods of Use | Sept. 23, 2004 | 10/948,588 | R# F# |

Rest Available Copy

| Docket No. | Title | Filing Date | Application No. | Assignment Reel and Frame Nos. |
|------------------------------------|--|-----------------|-----------------|--------------------------------|
| 15966-557 CIP1 CURA 57 CIP1 | Novel Fibroblast Growth Factor and Nucleic Acids Encoding Same | July 3, 2000 | 09/609,543 | R#011317 F#0748 |
| 15966-557A CURA 57A | Treatment of Inflammatory Bowel Disease Using Growth Factors | Nov. 6, 2001 | 09/992,840 | R#015497 F#0582 |
| 15966-557 OA CIP CURA 57 OA CIP | Fibroblast Growth Factor 20 and Methods of Use Thereof | Nov. 3, 2004 | 10/980,458 | R# F# |
| 15966-557 OA CURA 57 OA | Novel Fibroblast Growth Factors and Methods of Use Thereof | May 10, 2004 | 10/842,206 | R# F# |
| 15966-557RP CIP1 CURA 57RP CIP1 | Prophylactic and Therapeutic Uses of FGF-20 in Radiation Protection | Nov. 3, 2004 | 10/980,695 | R# F# |
| 15966-557 RP CURA 57 RP | Therapeutic Use of G53135-05 (FGF-20) in Radiation Protection | May 10, 2004 | 10/842,179 | R# F# |
| 15966-557 SNP CURA 57 SNP | Compositions and Methods of Use For a Fibroblast Growth Factor | Nov. 4, 2003 | 10/702,126 | R# F# |
| 15966-557 PO CURA 57 PO | Methods For Diagnosing and Treatment of Conditions That Alter Phosphate Transport in Mammals | August 20, 2003 | 10/644,349 | R#014925 F#0846 |
| 15966-557 FP CURA 57 FP | Formulations and Methods of Production of FGF-20 | Nov. 3, 2004 | 10/980,370 | R# F# |

Best Available Copy

| Docket No. | Title | Filing Date | Application No. | Assignment Reel and Frame Nos. |
|----------------------------------|---|-------------------|-----------------|---------------------------------|
| 15966-557 AM CURA 57 AM | Method of Preventing and Treating Alimentary Mucositis | Nov. 3, 2004 | 10/980,459 | R# F# |
| 15966-577 CURA 77 | Growth Factor Polypeptides and Nucleic Acids Encoding Same | Sept. 12, 2000 | 09/688,312 | R#015523 F#0696 |
| 15966-577 CON CURA 77 CON | Growth Factor Polypeptides and Nucleic Acids Encoding Same | April 1, 2005 | 11/096,308 | R# F# |
| 15966-577 A CURA 77 A | Growth Factor Polypeptides and Nucleic Acids Encoding Same | October 5, 2000 | 09/685,330 | R#011534 F#0346 Abandoned |
| 15966-577A CIP CURA 77A CIP | Growth Factor Polypeptides and Nucleic Acids Encoding Same | October 13, 2000 | 09/688,312 | R# F# Abandoned |
| 15966-577A CIP2 CURA 77A CIP2 | Growth Factor Polypeptides and Nucleic Acids Encoding Same | November 16, 2000 | 09/717,332 | R# F# Abandoned |
| 15966-577A CIP3 CURA 77A CIP3 | Growth Factor Polypeptides and Nucleic Acids Encoding Same | February 2, 2001 | 09/775,482 | R#012218 F#0294 Abandoned |